Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results - Business Update

Aug 26, 2026

Uploaded by Terk

Werewolf Therapeutics reports fourth-quarter and full-year 2023 financial results alongside a company business update. Management highlights upcoming clinical milestone plans for WTX-124, including additional Phase 1/1b dose-escalation data and recommended-dose expansion in early 2024, and initial clinical data for WTX-330 expected in the second quarter of 2024. The update also covers platform progress in preclinical programs, leadership transition with the retirement of the Chief Scientific Officer, and revised cash runway guidance through at least Q2 2025.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages3

Reading Time8 min

AccessFree to download

Recent Highlights and Upcoming Milestones

WTX-124

WTX-330

Preclinical Portfolio

Additional Updates

Financial Results for the Fourth Quarter and Full Year 2023

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 7, 2024 – Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024 – – WTX-124 recommended dose for expansion (RDE), initiation of monotherapy dose expansion arms and initial combination dose-escalation data also expected in the first half of 2024 – – Preliminary data from Phase 1 clinical trial of WTX-330 expected in the second quarter of 2024 – – Updated cash guidance provides runway through at least the second quarter of 2025 – WATERTOWN, Mass. , March 07, 2024 (GLOBE NEWSWIRE) --Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023. “Werewolf made considerable progress in 2023, setting up 2024 as a year of execution across our pipeline,” said Daniel J. Hicklin, Ph. D. , President and Chief Executive Officer of Werewolf. “In the first half of this year, we plan to present additional clinical data from our Phase 1/1b clinical trial of WTX-124, including updated monotherapy data and initial combination data, which we anticipate will build on the promising signals of antitumor activity and improved therapeutic index that we observed in the data presented at SITC last year. In addition, we plan to share data further demonstrating the performance of our platform in our preclinical programs at AACR. We also plan to share initial clinical data from WTX-330, our second clinical candidate, in the second quarter of 2024.” “Additionally, I would like to express my deep appreciation to Cindy Seidel-Dugan, Ph. D. , Werewolf’s Chief Scientific Officer, who is retiring effective March 29, 2024, after a long and successful career in the biopharmaceutical industry. Cindy was a founding member of the Werewolf Executive Team and has been instrumental in establishing Werewolf’s innovative science, developing our INDUKINE technology, and shepherding our lead candidates through the discovery and IND-enabling process. We have benefited greatly from Cindy’s significant expertise, and the strong scientific leadership team she has built that will ensure continued success going forward. We wish Cindy the very best in her retirement.” Recent Highlights and Upcoming Milestones WTX-124: a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule being developed as monotherapy and in combination with pembrolizumab in multiple solid tumor types. In November 2023, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, Werewolf presented firstin-human monotherapy data from the Phase 1/1b clinical trial of WTX-124 . These preliminary data established proof of mechanism for WTX-124 and proof of concept for Werewolf’s INDUKINE design hypothesis. In the first half of 2024, Werewolf expects to present additional interim dose-escalation data from the monotherapy dose-escalation arm, nominate a recommended dose for expansion and initiate monotherapy dose expansion arms. Additionally, Werewolf continues to progress combination dose escalation cohorts of the Phase 1/1b clinical trial and plans to report initial clinical data from this arm in the first half of 2024. WTX-330: a systemically delivered, conditionally activated Interleukin-12 (IL-12) INDUKINE molecule being developed in refractory and/or immunologically unresponsive tumors. Werewolf is progressing Study WTX-330x2101, its Phase 1, multi-center, open-label clinical trial evaluating WTX-330 as amonotherapy in patients with immunotherapy insensitive or resistant advanced or metastatic solid tumors or non-H

FAQs

What upcoming clinical data are planned for WTX-124 in 2024?

Werewolf plans to present additional interim dose-escalation data from the WTX-124 monotherapy arm, nominate a recommended dose for expansion, initiate monotherapy dose expansion arms, and report initial combination dose-escalation data in the first half of 2024.

When does the company expect initial clinical data for WTX-330?

Initial data from the Phase 1 study of WTX-330 are expected in the second quarter of 2024.

How has cash guidance been updated and what runway does it provide?

Updated cash guidance provides runway through at least the second quarter of 2025.

Aug 26, 2026

Uploaded by Terk